Unknown

Dataset Information

0

Immunological and clinical consequences of splenectomy in a multiple sclerosis patient treated with natalizumab.


ABSTRACT:

Objective

Here we report a case of a splenectomized white woman with natalizumab-associated progressive multifocal leukoencephalopathy (PML), occurring as early as after 11 infusions and provide blood fluorescence-activated cell sorting (FACS) analyses before and after natalizumab treatment.

Design

This is a report of a single case with immunological studies.

Methods

Methods comprised neurologic examination, magnetic resonance imaging, and cerebrospinal fluid (CSF) studies as well as immune cell FACS analyses from blood.

Results

Diagnosis of PML was established after positive John Cunningham virus (JCV) DNA was detected in the CSF. An immune reconstitution inflammatory syndrome was treated with repeated cycles of steroid pulses and intravenous immunoglobulins. Reduced numbers of memory B cells, which might play an important role in antiviral immune response, were detected in the blood. Moreover the percentage of CD19+ B cells was elevated in our post-splenectomy patient as compared to a control cohort of multiple sclerosis (MS) patients under natalizumab therapy.

Conclusion

Splenectomy may increase the risk for the development of natalizumab-associated PML via effects on the B cell compartment. It may be regarded as a risk factor in MS patients independent from the duration of disease.

SUBMITTER: Lee DH 

PROVIDER: S-EPMC3854515 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Immunological and clinical consequences of splenectomy in a multiple sclerosis patient treated with natalizumab.

Lee De-Hyung DH   Waschbisch Anne A   Lämmer Alexandra B AB   Doerfler Arnd A   Schwab Stefan S   Linker Ralf A RA  

Journal of neuroinflammation 20131009


<h4>Objective</h4>Here we report a case of a splenectomized white woman with natalizumab-associated progressive multifocal leukoencephalopathy (PML), occurring as early as after 11 infusions and provide blood fluorescence-activated cell sorting (FACS) analyses before and after natalizumab treatment.<h4>Design</h4>This is a report of a single case with immunological studies.<h4>Methods</h4>Methods comprised neurologic examination, magnetic resonance imaging, and cerebrospinal fluid (CSF) studies  ...[more]

Similar Datasets

| S-EPMC5497532 | biostudies-other
| S-EPMC2323568 | biostudies-literature
| S-EPMC8000901 | biostudies-literature
| S-EPMC3557363 | biostudies-literature
| S-EPMC7455689 | biostudies-literature
| S-EPMC8105883 | biostudies-literature
| S-EPMC3543243 | biostudies-literature
| S-EPMC8573181 | biostudies-literature